91直播

Hospitals must start using 鈥渟mart鈥� intravenous (IV) infusion technology to its full potential if they are to prevent dangerous drug errors, University of Manchester researchers have found.

鈥楽mart pumps鈥�-  which automatically calculate the dose and rate of different drugs before they are pumped into a vein  - prevent potentially fatal errors by stopping the administration of the wrong rate.

But according to the study published in BMJ Open Quality, though the technology probably saved the lives of 110 people in two Trusts over a year, it has largely failed to be adopted by hospitals.

Though many IV pumps used in hospitals have a smart capability, most trusts do not utilise the functionality because they are difficult to configure and maintain.

Smart pumps are usually configured by a pharmacist and checked by a consultant or senior nurse. Conventional pumps, however, are set by ward staff who calculate and input infusion rates themselves - increasing the risk of drug errors.

The risks are illustrated by previous work from the 91直播 team, who demonstrated that 1 in 10 IV drug administrations are associated with an error, and up to 1 in 10 of those were associated with harm.

In the BMJ Open Quality study, almost 1.5 million IV infusions were administered over one year (644 052 patient bed days), but only 45% (745,170) of these were administered with smart pumps capability enabled.

There were 6,067 infusions that exceeded the dose limits of the pumps. Subject matter experts were asked to rate severity of all adverse events on a scale of 0-no harm to 10-death and they found 89% of these events were unlikely to cause patients any harm.

However, smart pumps prevented 668 moderate to severe harm administration errors (a rate of 0.9/1000 IV administrations) and included blood thinning medication, drugs affecting heart rhythm and drugs used to stop epileptic seizures.

Of 17.9/1000 intercepted drug administration errors, the most common drugs to trigger an alert were antibiotics (2,979 alerts in 134,821 infusions) but there was a relatively low potential for harm from these infusions (1.01/1000 administrations). 

The highest incidence of potentially harmful adverse events was for parenteral anticoagulants (24.16 per 1000 administrations which risks severe bleeding. There have been reports of these events in the NHS recently.

Drugs with greatest potential for harm with an adverse event were parenteral anticoagulants at 24.16/1000 administrations, antiarrhythmics at 21.8/1000 administrations and antiepileptics at 20.86/1000 administrations. 

Some alerts were triggered because the pumps were programmed with limits that did not reflect practice in the clinic, which suggested routine practice might contribute to patient harm.

In another paper published in the journal Drug Safety at the same time, the research team collaborated with academics, patient advocacy groups and senior clinicians to develop and publish guidelines to support organisations in their adoption of smart pumps, so they are used to their full potential across the NHS and infuse drugs at standardised concentrations.

A symposium of 36 clinical and academic medication safety experts proposed strategic recommendations to support the implementation of medication administration technology to improve medication safety.

Both papers were the result of collaborations the University of Manchester, pump manufacturers Becton-Dickinson - who funded the study- and the NHS who shared their data with the team.

Lead author is a researcher at The University of Manchester based in the division of pharmacy and optometry and a practising pharmacist.

He said: 鈥淚ntravenous infusion errors leading to fatalities are extremely  rare event; the vast majority of IV infusions are safe.

鈥淏ut avoidable harm associated with medication is a persistent problem in health systems and the use of preprogramed infusion devices can mitigate and reducing their incidence

鈥淐onfiguration of these pumps is often poorly implemented 鈥� with little consistency between hospitals.

鈥淓ven though smart pumps have been available for around 20 years and are routinely used in the USA - we only 20 to 30 trusts use them in some way, and even fewer to their full capability. Within a few years, all IV pumps will have smart functionality, so it makes sense for hospitals to make full use of them.鈥�

He added: 鈥淰ariation in the manner in which medicines are prepared and used within complex modern healthcare systems exacerbates these challenges, so a strategic human-centred approach is needed to support their implementation.

鈥淪mart functionality has a role in intravenous medication safety, but only as part of a programme of interventions to standardise intravenous medication practice.

鈥淭hey aren鈥檛 a panacea but like a seat belt in a car in that they can avoid catastrophic injuries to patients.鈥�

Developing Strategic Recommendations for Implementing Smart Pumps in Advanced Healthcare Systems to Improve Intravenous Medication Safety is available

The impact of drug error reduction software on preventing harmful adverse drug events in England: a retrospective database study is available